{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:58Z","timestamp":1792271398297,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K20159"],"award-info":[{"award-number":["16K20159"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15K10605"],"award-info":[{"award-number":["15K10605"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04783-8","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:53:08Z","timestamp":1750827188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Owari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia N.","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunta","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Morizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Kikugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"4783_CR1","doi-asserted-by":"publisher","first-page":"04109","DOI":"10.7189\/jogh.13.04109","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J (2023) The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 13:04109. https:\/\/doi.org\/10.7189\/jogh.13.04109","journal-title":"J Glob Health"},{"key":"4783_CR2","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. EAU Guidelines Office, Arnhem, The Netherlands. https:\/\/uroweb.org\/guidelines"},{"key":"4783_CR3","doi-asserted-by":"publisher","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2024) ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 35(6):485\u2013490. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001","DOI":"10.1016\/j.annonc.2024.03.001"},{"issue":"4","key":"4783_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA (2024) NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024. J Natl Compr Canc Netw 22(4):216\u2013225. https:\/\/doi.org\/10.6004\/jnccn.2024.0024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4783_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R et al (2021) EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Assoc Urol 79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Assoc Urol"},{"issue":"12","key":"4783_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP (2021) Enfortumab Vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"key":"4783_CR7","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/cancers16132398","volume":"16","author":"VK Srinivasalu","year":"2024","unstructured":"Srinivasalu VK, Robbrecht D (2024) Advancements in First-Line treatment of metastatic bladder cancer: EV-302 and Checkmate-901 insights and future directions. Cancers (Basel) 16:2398. https:\/\/doi.org\/10.3390\/cancers16132398","journal-title":"Cancers (Basel)"},{"key":"4783_CR8","doi-asserted-by":"publisher","unstructured":"Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano Gauna DE, Fornarini G, Li JR, Gumus M, Mar N, Narayanan S, Yu X, Gorla S, Homet Moreno, van der Heijden BMS (2023) [LBA6] EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV1P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC). Ann Oncol 34:S1340. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.106","DOI":"10.1016\/j.annonc.2023.10.106"},{"issue":"8","key":"4783_CR9","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Kl\u00fcmper","year":"2023","unstructured":"Kl\u00fcmper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, B\u00fcttner T, Hahn O, Gr\u00fcnwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zsch\u00e4bitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, H\u00f6lzel M, Eckstein M (2023) Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab Vedotin resistance. Clin Cancer Res 29(8):1496\u20131505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1764","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4783_CR10","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S, Hahn O, B\u00fcttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Nieders\u00fc\u00df-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-Gonz\u00e1lez JA, Boormans J, Junker K, Hartmann A, Gr\u00fcnwald V, H\u00f6lzel M, Eckstein M (2024) NECTIN4 amplification is frequent in solid tumors and predicts enfortumab Vedotin response in metastatic urothelial Cancer. J Clin Oncol 42(20):2446\u20132455. https:\/\/doi.org\/10.1200\/JCO.23.01983","journal-title":"J Clin Oncol"},{"issue":"3","key":"4783_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/iju.15109","volume":"30","author":"M Miyake","year":"2023","unstructured":"Miyake M, Oda Y, Nishimura N, Shimizu T, Fujii T, Fujimoto K (2023) Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice. Int J Urol 30(3):328\u2013330. https:\/\/doi.org\/10.1111\/iju.15109","journal-title":"Int J Urol"},{"key":"4783_CR12","doi-asserted-by":"publisher","first-page":"154072","DOI":"10.1016\/j.prp.2022.154072","volume":"237","author":"M Miyake","year":"2022","unstructured":"Miyake M, Miyamoto T, Shimizu T, Ohnishi S, Fujii T, Nishimura N, Oda Y, Morizawa Y, Hori S, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K (2022) Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: an intra-patient variability of Nectin-4 expression. Pathol Res Pract 237:154072. https:\/\/doi.org\/10.1016\/j.prp.2022.154072","journal-title":"Pathol Res Pract"},{"issue":"16","key":"4783_CR13","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","volume":"25","author":"R Seiler","year":"2019","unstructured":"Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, van de Fransen EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall\u2019Era M, van der Heijden MS, Wright JL, Black PC (2019) Divergent biological response to neoadjuvant chemotherapy in Muscle-invasive bladder Cancer. Clin Cancer Res 25(16):5082\u20135093. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1106","journal-title":"Clin Cancer Res"},{"issue":"18","key":"4783_CR14","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu CE, Sj\u00f6str\u00f6m M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J (2021) Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial Cancer mediates sensitivity to enfortumab Vedotin. Clin Cancer Res 27(18):5123\u20135130. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4175","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4783_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327\u2013344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"4783_CR16","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","volume":"4","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to Antibody-Drug conjugates. Int J Mol Sci 4(11):9674. https:\/\/doi.org\/10.3390\/ijms24119674","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4783_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molonc.2011.12.002","volume":"6","author":"N Miura","year":"2012","unstructured":"Miura N, Takemori N, Kikugawa T, Tanji N, Higashiyama S, Yokoyama M (2012) Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis. Mol Oncol 6(3):311\u2013322. https:\/\/doi.org\/10.1016\/j.molonc.2011.12.002","journal-title":"Mol Oncol"},{"issue":"1","key":"4783_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12885-020-07717-0","volume":"21","author":"S Okamura","year":"2021","unstructured":"Okamura S, Yoshino H, Kuroshima K, Tsuruda M, Osako Y, Sakaguchi T, Yonemori M, Yamada Y, Tatarano S, Nakagawa M, Enokida H (2021) EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive MicroRNAs in bladder cancer. BMC Cancer 21(1):48. https:\/\/doi.org\/10.1186\/s12885-020-07717-0","journal-title":"BMC Cancer"},{"issue":"7","key":"4783_CR19","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/cancers12071942","volume":"12","author":"M Miyake","year":"2020","unstructured":"Miyake M, Hori S, Itami Y, Oda Y, Owari T, Fujii T, Ohnishi S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K (2020) Supplementary oral Anamorelin mitigates anorexia and skeletal muscle atrophy induced by gemcitabine plus cisplatin systemic chemotherapy in a mouse model. Cancers (Basel) 12(7):1942. https:\/\/doi.org\/10.3390\/cancers12071942","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4783_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1124\/jpet.109.162768","volume":"332","author":"M Miyake","year":"2010","unstructured":"Miyake M, Ishii M, Koyama N, Kawashima K, Kodama T, Anai S, Fujimoto K, Hirao Y, Sugano K (2010) 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27\/Kip1 and G1\/G0 arrest. J Pharmacol Exp Ther 332(3):795\u2013802. https:\/\/doi.org\/10.1124\/jpet.109.162768","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"4783_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3892\/ol.2012.662","volume":"3","author":"M Miyake","year":"2012","unstructured":"Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y (2012) 5-fluorouracil enhances the antitumor effect of Sorafenib and Sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett 3(6):1195\u20131202. https:\/\/doi.org\/10.3892\/ol.2012.662","journal-title":"Oncol Lett"},{"issue":"22","key":"4783_CR22","doi-asserted-by":"publisher","first-page":"36099","DOI":"10.18632\/oncotarget.16432","volume":"8","author":"M Miyake","year":"2017","unstructured":"Miyake M, Hori S, Morizawa Y, Tatsumi Y, Toritsuka M, Ohnishi S, Shimada K, Furuya H, Khadka VS, Deng Y, Ohnishi K, Iida K, Gotoh D, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Konishi N, Fujimoto K (2017) Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. Oncotarget 8(22):36099\u201336114. https:\/\/doi.org\/10.18632\/oncotarget.16432","journal-title":"Oncotarget"},{"key":"4783_CR23","doi-asserted-by":"publisher","unstructured":"The Gene Ontology Consortium (2019) The gene ontology resource: 20 years and still going strong. Nucleic Acids Res 47(D1):D330\u2013D338. https:\/\/doi.org\/10.1093\/nar\/gky1055","DOI":"10.1093\/nar\/gky1055"},{"issue":"Database issue","key":"4783_CR24","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkm882","volume":"36","author":"M Kanehisa","year":"2008","unstructured":"Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, Yamanishi Y (2008) KEGG for linking genomes to life and the environment. Nucleic Acids Res 36(Database issue):D480\u2013D484. https:\/\/doi.org\/10.1093\/nar\/gkm882","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"4783_CR25","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.3390\/cancers13215500","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L (2021) Molecular classification of bladder urothelial carcinoma using NanoString-Based gene expression analysis. Cancers (Basel) 13(21):5500. https:\/\/doi.org\/10.3390\/cancers13215500","journal-title":"Cancers (Basel)"},{"key":"4783_CR26","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1016\/j.tranon.2024.102269","volume":"52","author":"S Mokkapati","year":"2025","unstructured":"Mokkapati S, Manyam G, Steinmetz AR, Tholomier C, Martini A, Choi W, Czerniak B, Lee BH, Dinney CP, McConkey DJ (2025) Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery. Transl Oncol 52:102269. https:\/\/doi.org\/10.1016\/j.tranon.2024.102269","journal-title":"Transl Oncol"},{"key":"4783_CR27","doi-asserted-by":"publisher","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network;, Weinstein JN, Kwiatkowski DJ, Lerner SP(2017) (2018). Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171(3):540\u2013556.e25. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007. Erratum in: Cell 174(4):1033. https:\/\/doi.org\/10.1016\/j.cell.2018.07.036","DOI":"10.1016\/j.cell.2017.09.007"},{"issue":"4","key":"4783_CR28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jnci\/58.4.881","volume":"58","author":"S Rasheed","year":"1977","unstructured":"Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P (1977) Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 58(4):881\u2013890. https:\/\/doi.org\/10.1093\/jnci\/58.4.881","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"4783_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G\u00fcm\u00fc\u015f M, Mar N, Loriot Y, Fl\u00e9chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS, EV-302 Trial Investigators (2024) Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"issue":"24","key":"4783_CR30","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2217\/fon-2021-0273","volume":"17","author":"MD Galsky","year":"2021","unstructured":"Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A (2021) Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303. Future Oncol 17(24):3137\u20133150. https:\/\/doi.org\/10.2217\/fon-2021-0273","journal-title":"Future Oncol"},{"issue":"6suppl","key":"4783_CR31","doi-asserted-by":"publisher","first-page":"AbstractTPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","volume":"40","author":"T Powles","year":"2022","unstructured":"Powles T, Drakaki A, Teoh JY, Grande E, Fontes-Sousa M, Porta C, Wu E, Goluboff ET, Ho S, Hois S, Gupta AK, Catto JWF (2022) A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D)\u2009+\u2009tremelimumab (T)\u2009+\u2009enfortumab Vedotin (EV) or D\u2009+\u2009EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). J Clin Oncol 40(6suppl):AbstractTPS579. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS579","journal-title":"J Clin Oncol"},{"issue":"6","key":"4783_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327\u2013344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4783_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tcb.2022.08.002","volume":"33","author":"A Zabini","year":"2023","unstructured":"Zabini A, Zimmer Y, Medov\u00e1 M (2023) Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteins. Trends Cell Biol 33(1):5\u20138. https:\/\/doi.org\/10.1016\/j.tcb.2022.08.002","journal-title":"Trends Cell Biol"},{"issue":"3","key":"4783_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1139\/bcb-2021-0348","volume":"100","author":"S Wang","year":"2022","unstructured":"Wang S, Zhang W (2022) Small proline-rich protein 1A promotes lung adenocarcinoma progression and indicates unfavorable clinical outcomes. Biochem Cell Biol 100(3):199\u2013212. https:\/\/doi.org\/10.1139\/bcb-2021-0348","journal-title":"Biochem Cell Biol"},{"issue":"5","key":"4783_CR35","doi-asserted-by":"publisher","first-page":"e0266620","DOI":"10.1371\/journal.pone.0266620","volume":"17","author":"K Yamakawa","year":"2022","unstructured":"Yamakawa K, Koyanagi-Aoi M, Uehara K, Masuda A, Yanagimoto H, Toyama H, Fukumoto T, Kodama Y, Aoi T (2022) Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. PLoS ONE 17(5):e0266620. https:\/\/doi.org\/10.1371\/journal.pone.0266620","journal-title":"PLoS ONE"},{"key":"4783_CR36","doi-asserted-by":"publisher","unstructured":"Li J, Tang LL, Ma J (2022) Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients. BMC Cancer 22(1):714. https:\/\/doi.org\/10.1186\/s12885-022-09722-x. Erratum in: (2022) BMC Cancer 22(1):755. https:\/\/doi.org\/10.1186\/s12885-022-09865-x","DOI":"10.1186\/s12885-022-09722-x"},{"issue":"2","key":"4783_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3892\/or.2024.8857","volume":"53","author":"T Miyamoto","year":"2025","unstructured":"Miyamoto T, Fukase N, Kawamoto T, Fujiwara S, Hara H, Sawada R, Nakamatsu Y, Mifune Y, Kakutani K, Hoshino Y, Hayashi S, Matsumoto T, Matsushita T, Koyanagi-Aoi M, Aoi T, Takemori T, Yahiro S, Kuroda R, Akisue T (2025) SPRR1A is a potential therapeutic target for osteosarcoma: in vitro and in vivo evaluations using generated artificial osteosarcoma cancer stem cell\u2013like cells. Oncol Rep 53(2):24. https:\/\/doi.org\/10.3892\/or.2024.8857","journal-title":"Oncol Rep"},{"key":"4783_CR38","doi-asserted-by":"publisher","first-page":"RP89486","DOI":"10.7554\/eLife.89486","volume":"12","author":"Y Ban","year":"2024","unstructured":"Ban Y, Zou Y, Liu Y, Lee S, Bednarczyk RB, Sheng J, Cao Y, Wong STC, Gao D (2024) Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer. Elife 12:RP89486. https:\/\/doi.org\/10.7554\/eLife.89486","journal-title":"Elife"},{"issue":"4","key":"4783_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskj\u00f8t L, H\u00f6glund M, Lerner SP, Real FX, Radvanyi F, Bladder Cancer Molecular Taxonomy Group (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77(4):420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006","journal-title":"Eur Urol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04783-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:53:09Z","timestamp":1750827189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04783-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4783"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04783-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kiyohide Fujimoto received speaking\/lecture fees and Makito Miyake received speaking\/lecture and consultation\/advisory fees from Astellas Pharma Inc. Other authors disclose no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board: ID: 1256\/2891.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"62"}}